Registries Rising: FDA Looking At TNF Inhibitors; AHRQ Updates Standards
Executive Summary
The FDA Amendments Act of 2007 gave the agency many new safety powers and the potential for promotional restrictions and post-marketing fines have understandably received much industry attention. But FDA also appears to be drawing upon its beefed-up authority to increase use of a much older, low-tech safety effort: the patient registry
You may also be interested in...
Drug Safety In Pregnant Women: FDA Seeks Alternatives To Registries
Stakeholder meeting will address poor enrollment rates and other issues that undermine the utility of pregnancy registries, as well as the use of alternatives, such as case control studies and claims-based database studies.
Building A Better Patient Registry: Keep It Simple, But Let It Be Big
The evolving data needs of payers and regulators are encouraging product sponsors to rely more on patient registries with the hope of generating vital information at a lower cost
Building A Better Patient Registry: Keep It Simple, But Let It Be Big
The evolving data needs of payers and regulators are encouraging product sponsors to rely more on patient registries with the hope of generating vital information at a lower cost